Kylo-0603

KYLO-0603 is an orally active and selective THR-β agonist with an EC50 of 31.07 nM. It effectively reduces serum cholesterol and low-density lipoprotein cholesterol levels. By activating THR-β receptors, KYLO-0603 enhances the expression of THR-regulated genes like iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone-responsive (Thrsp) gene, while it inhibits the expression of inflammatory and fibrosis-related genes, including low-density lipoprotein receptor (LDL-R) gene. This compound is applicable for the study of metabolic associated steatohepatitis (MASH) and liver fibrosis.

C(NC(CCCCCNC(COC1=CC(C)=C(CC2=CC(C(C)C)=C(O)C=C2)C(C)=C1)=O)=O)(COCCC(NCCCCCCO[C@H]3[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)=O)(COCCC(NCCCCCCO[C@H]4[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)=O)COCCC(NCCCCCCO[C@H]5[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)=O